EP1263445A1 - Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal - Google Patents

Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal

Info

Publication number
EP1263445A1
EP1263445A1 EP01910045A EP01910045A EP1263445A1 EP 1263445 A1 EP1263445 A1 EP 1263445A1 EP 01910045 A EP01910045 A EP 01910045A EP 01910045 A EP01910045 A EP 01910045A EP 1263445 A1 EP1263445 A1 EP 1263445A1
Authority
EP
European Patent Office
Prior art keywords
analogue
derivative
use according
metronidazole
hydrogen pump
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01910045A
Other languages
German (de)
English (en)
Inventor
Ian Whitcroft
Andrew Ilchyshyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00301951A external-priority patent/EP1133987A1/fr
Application filed by Individual filed Critical Individual
Publication of EP1263445A1 publication Critical patent/EP1263445A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Definitions

  • the present invention relates to the treatment of skin 5 conditions such as rosacea and similar inflammatory dermatoses, and m particular to the treatment of certain kinds of rosacea, and also perioral papular and pustular acne, and other papulopustular dermatoses.
  • Rosacea is a chronic inflammatory disease which affects the face. It is characterised by episodic flushing, erythema, and telangiectasia affecting the cheeks, chin, forehead, and nose. It may be further complicated by inflammatory swelling, papules and pustules.
  • H. Pylori Gram-negative bacterium Helicobacter pylori
  • rosacea and similar inflammatory skin dermatoses can be effectively treated by administering to a patient a treatment regime comprising I) erythromycm, clarithromycm or an analogue or derivative thereof, n) metronidazole or an analogue or derivative thereof, and m) a gastrointestinal hydrogen pump inhibitor, such as omeprazole or an analogue or derivative thereof.
  • the three drugs may be formulated for simultaneous, separate or sequential use.
  • the triple drug combination according to the present invention functions in achieving the desired results.
  • One possibility is that there may be a causal relationship between the dermatoses to be treated and H. pylori , such that eradication of H. pylori may lead to resolution of these dermatoses.
  • Another possibility is that as, certain instances, the presence of H. pylori has been found m pustules on the skin, the triple drug combination may act directly to eradicate that external form of H. pylori .
  • triple drug combination works m another manner, such that any apparent relationship between its use m the present invention and H .pylori may simply be coincidental, such that further study will be necessary elucidate its precise mode of action Description of the Invention
  • the preferred treatment regime comprises erythromycm or clarithromycm, metronidazole and omeprazole, and the most preferred treatment regime comprises clarithromycm, metronidazole and omeprazole.
  • analogues or derivatives of any of these drugs may be used provided that their combined administration achieves the desired result.
  • another similar-acting macrolide antibiotic to erythromycm or clarithromycm may be used, for instance azithromycm or dirithromyc .
  • lanzoprazole or any other drug which acts to inhibits a gastrointestinal hydrogen pump may be used instead of omeprazole.
  • the three drugs may be useful which have a similar or equivalent pharmacological mode of action to the drugs named above.
  • Pharmaceutically- acceptable salt forms of the drugs may also be used.
  • Treatment may be by administration of the three drugs by any suitable means. Conveniently, however, the three drugs will be administered by one or a combination of oral administration, topical application to a patient's skin, or parenteral administration, e.g. intravenous, intramuscular or subcutaneous administration. For instance, one or more of the three drugs may be formulated for administration by a different route to the other drug(s) . Typically, it is desirable to administer omeprazole or an analogue thereof orally, but the other drugs may be formulated for oral, topical or parenteral administration, or any combination thereof. For instance, it may be preferred to administer omeprazole orally and the other two drugs topically, optionally as a combined topical formulation.
  • the triple drug combination may take the form of separate pills containing each of the separate drugs, for simultaneous, separate or sequential administration.
  • the three drugs will be combined into a single dosage form, preferably a tablet, capsule or linctus, for patient convenience.
  • the drugs are incorporated into a suitable pharmaceutically-acceptable carrier.
  • suitable pharmaceutically-acceptable carrier Such formulations have not been disclosed in the prior art, and constitute further aspects of the claimed invention.
  • the relative proportions of the three drugs necessary for effective treatment may vary depending on the route of administration, and the particular patient to be treated.
  • a patient will receive 200 to 600 mg, preferably 300 to 500 mg of erythromycin, clarithromycin or an analogue thereof, 200 to 500 mg, preferably 300 to 500 mg, metronidazole, and 10 to 100 mg, preferably 20 to 60 mg, omeprazole, on a daily basis.
  • a particularly preferred treatment regime comprises about 250 mg erythromycin, clarithromycin or an analogue thereof, about 400 mg metronidazole and about 20 mg omeprazole.
  • Treatment periods vary from patient to patient, from one week to a number of years .
  • a score of one is given if less than half the area involved is affected by that parameter, and a score of two if half or more of the area is affected.
  • the scores for the different parameters in the different facial areas are added together to give a total score for the patient.
  • Each patient was subjected to clinical photography, and then treated with an oral dosage of 20 mg omeprazole, 400 mg metronidazole, and 250 mg clarithromycin for one week.
  • Disease severity scoring and clinical photography were repeated at the end of weeks 6, 12, 18, and 24, and fourteen patients were followed for a period of 52 weeks.

Abstract

L'invention concerne l'utilisation i) d'érythromycine, de clarithromycine ou d'un analogue ou d'un dérivé de ces composés, ii) de métronidazole ou d'un analogue ou d'un dérivé de ce composé, et iii) d'oméprazole ou d'un analogue ou d'un dérivé de ce composé, pour la fabrication d'un médicament destiné au traitement de troubles faisant partie du groupe comprenant des dermatoses inflammatoires, et en particulier l'acné rosacée papulopustuleuse ainsi que des dermatoses papulopustuleuses inflammatoires du même type.
EP01910045A 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal Withdrawn EP1263445A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00301951 2000-03-09
EP00301951A EP1133987A1 (fr) 2000-03-09 2000-03-09 Traitement de dermatoses inflammatoires avec une combinaison d'erythromycine ou clarithromycine, métronidazole et un inhibiteur des pompes à hydrogène
US18896100P 2000-03-10 2000-03-10
US188961P 2000-03-10
PCT/GB2001/001047 WO2001066117A1 (fr) 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal

Publications (1)

Publication Number Publication Date
EP1263445A1 true EP1263445A1 (fr) 2002-12-11

Family

ID=26073033

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01910045A Withdrawn EP1263445A1 (fr) 2000-03-09 2001-03-09 Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal

Country Status (4)

Country Link
EP (1) EP1263445A1 (fr)
AU (1) AU3762801A (fr)
CA (1) CA2413923A1 (fr)
WO (1) WO2001066117A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617709A (zh) * 2001-12-13 2005-05-18 兰贝克赛实验室有限公司 克拉霉素的稳定局部制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
TW276996B (fr) * 1992-04-24 1996-06-01 Astra Ab
WO1995018612A1 (fr) * 1994-01-05 1995-07-13 Aktiebolaget Astra Procede de traitement du psoriasis par omeprazole ou autres composes apparentes
EE03378B1 (et) * 1994-07-08 2001-04-16 Astra Aktiebolag Omeprasooli magneesiumisoola sisaldav peroraalne ravimvorm
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
JPH10158172A (ja) * 1996-11-29 1998-06-16 Takeshi Azuma 肝性脳症治療剤又は肝性脳症予防剤
US6017950A (en) * 1997-08-05 2000-01-25 Millennium Pharmaceuticals, Inc. Methods for controlling gram negative bacteria in mammals
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0166117A1 *

Also Published As

Publication number Publication date
AU3762801A (en) 2001-09-17
WO2001066117A1 (fr) 2001-09-13
CA2413923A1 (fr) 2001-09-13

Similar Documents

Publication Publication Date Title
EP1363600B1 (fr) Formulations liquides pour la prevention et le traitement d'affections et de troubles des muqueuses
Mehrabi et al. Therapeutic agents in perioperative third molar surgical procedures
US20180264021A1 (en) Treatment of papulopustular rosacea with ivermectin
ES2389539T3 (es) Métodos y composiciones para el tratamiento del asma
CN105362286A (zh) 用于治疗哺乳动物的内和外耳感染的耳用组合物
CA2822320A1 (fr) Composition pour le traitement d'etats pathologiques de la peau
Schaller et al. State of the art: systemic rosacea management
US9125927B2 (en) Compositions comprising avermectin/azelaic acid compounds useful for treating, e.g., rosacea
US20210128548A1 (en) External preparation comprising pyridonecarboxylic acid derivative
US20090163455A1 (en) Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea
CN113274384B (zh) 驴食草酚在制备防治溃疡性结肠炎的药物中的应用及其药物
KR20190100442A (ko) 이염을 치료하기 위한 조성물 및 방법
WO2001066117A1 (fr) Traitement de dermatoses inflammatoires a base d'erythromycine ou de clarithromycine ainsi que de metronidazole agissant comme inhibiteur du pompage d'hydrogene gastro-intestinal
EP1133987A1 (fr) Traitement de dermatoses inflammatoires avec une combinaison d'erythromycine ou clarithromycine, métronidazole et un inhibiteur des pompes à hydrogène
US20140288102A1 (en) Prevention of recurrences of urethral strictures following conventional therapy
JP2002308764A (ja) 眼科用医薬組成物
Vardas et al. Amiodarone for the restoration of sinus rhythm in patients with atrial fibrillation
EP3251676A1 (fr) Lavement pour application rectale
EP1670464A1 (fr) Compositions et procedes pour le traitement topique ou la prevention topique d'etats pathologiques de la peau
US20090197956A1 (en) Treatment of acute otitis media with xylitol and n-acetylcysteine
US6693100B1 (en) Pharmaceutical compositions for treating psoriasis
EP3664786B1 (fr) Méthode de traitement du syndrome de schnitzler
KR20170099911A (ko) 파라세타몰 주사 제제
WO2022094685A1 (fr) Composition, composition pharmaceutique, utilisation d'une composition topique stable comprenant une nanoémulsion, et d'au moins un composé anti-leishmaniose, et méthodes pour le traitement de la leishmaniose cutanée
WO2023108074A1 (fr) Nouvelles compositions de salvinorine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20031024

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040505